An observational study in Cancer, Cancer Metastatic and NTRK Gene Fusion Overexpression, sponsored by Centre Leon Berard. Recruiting at 41 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-02.
Sponsored by Centre Leon Berard · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This registry will make it possible to describe real life management of patients with rare actionable fusions and to better understand these cancers. In addition of clinical data from the medical files, a quality of life questionnaire (QLQ-C30) will be complete at inclusion, at each new treatment and then every 6 months. The patients will be followed for a period of at least 2 years after the inclusion.
This TRacKING registry is a European collaborative tool to improve the management of patients with actionable fusions, by sharing of data from rare tumor indications.
Patient's inclusion
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 500 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Centre Leon Berard is the lead sponsor of 211 studies on the registry; 62 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient with histologically-confirmed cancer that harboring a rare actionnable fusion, treated in a European center
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Data collection from the medical file * Quality of life questionnaire (QLQC30) at inclusion, at each change of treatment and then every 6 months
Overall Survival
To describe the survival rate of patients with solid cancers harboring a NTRK fusion or other rare actionable fusion in real-life practice, according to overall survival (OS)
Time frame: 2 years
Management of patient with actionable fusion
Treatment scheme : number of line and type of treatments
Time frame: up to 48 months
Time to relapse
Time frame: up to 48 months
Progression Free Survival (PFS)
Time frame: after 6, 12 and 24 months
Incidence of long-term responders
long term responders =: \> 24 months
Time frame: up to 48 months
Quality of life of patient
To evaluate patient-reported outcomes concerning individual QoL according to QLQ-C30 (EORTC Quality of Life questionnaires)
Time frame: After 6, 12, 18, 24, 30, 36, 42, 48 months
Time to relapse for fusion-targeting treatments
Time frame: up to 48 months
Overall survival for patient treated by fusion-targeting treatments
Time frame: 2 years
PFS for patient treated by fusion-targeting treatments
Progression free survival
Time frame: After 6, 12, 24 months of treatment by fusion targeting treatments
Incidence of long-term responders for patient treated by fusion-targeting treatments
\> 24 months
Time frame: up to 48 months
Quality of life of patient treated by fusion-targeting treatments
using QLQC30 (EORTC Quality of Life questionnaires)
Time frame: After 6, 12, 18, 24, 30, 36, 42, 48 months of fusion-targeting treatments
Safety : Nature of adverse reaction (for treatment targeting a fusion)
Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.
Time frame: up to 48 months
Safety : Frequency of adverse reaction (for treatment targeting a fusion)
Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.
Time frame: up to 48 months
Safety : Severity of adverse reaction (for treatment targeting a fusion)
Using Common Terminology Criteria for Adverse Events (CTCAE) V5.0.
Time frame: up to 48 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Jun 2025, 48 months after the start.
Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 48 months is below that.
Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.